Alirocumab 150 MG/ML subcutaneous injection + Matching Placebo subcutaneous injection
ApprovedTerminated 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Saphenous Vein Graft Atherosclerosis
Conditions
Saphenous Vein Graft Atherosclerosis
Trial Timeline
Aug 4, 2018 → Jul 31, 2020
NCT ID
NCT03542110About Alirocumab 150 MG/ML subcutaneous injection + Matching Placebo subcutaneous injection
Alirocumab 150 MG/ML subcutaneous injection + Matching Placebo subcutaneous injection is a approved stage product being developed by Regeneron Pharmaceuticals for Saphenous Vein Graft Atherosclerosis. The current trial status is terminated. This product is registered under clinical trial identifier NCT03542110. Target conditions include Saphenous Vein Graft Atherosclerosis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03542110 | Approved | Terminated |
Competing Products
2 competing products in Saphenous Vein Graft Atherosclerosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Aspirin + Ticagrelor | AstraZeneca | Approved | 85 |
| Atorvastatin 80 mg daily + Atorvastatin 10 mg daily | Pfizer | Phase 3 | 76 |